Tier 4 — mechanistic

New Perspectives for Fisetin

Grynkiewicz G, Demchuk OM
Frontiers in Chemistry 2019 7:697

Bibliography

PubMed
PMID 31750288
PubMed Central
PMC6842927
DOI
10.3389/fchem.2019.00697
Funding
Not explicitly stated in the reviewed sections; conducted at the Pharmaceutical Research Institute, Warszawa, Poland.
Competing interests
Not stated in the reviewed sections.

Study snapshot

DesignNarrative review of fisetin's chemistry as a flavonol, its antioxidant and cytoprotective properties, and — its main focus — methods for its chemical preparation/synthesis and their suitability for pharmaceutical-grade production, alongside a survey of its emerging anti-inflammatory, chemopreventive, chemotherapeutic and senotherapeutic applications.
ModelNot applicable — chemistry and literature review.
SampleNot applicable.
InterventionNot applicable.
DurationNot applicable.
EndpointsNot applicable — review of synthetic chemistry routes and pharmacological literature.

What the study showed, in plain terms

As fisetin has moved from a minor dietary flavonoid to a compound of serious pharmaceutical interest — including as a senolytic — the practical question of how to make enough pharmaceutical-grade fisetin, reliably and affordably, becomes important. This review addresses that chemistry question.

Two Polish chemists survey fisetin's basic structure and antioxidant chemistry, then focus in detail on synthetic routes for producing fisetin and their suitability for scaled-up pharmaceutical manufacture, while also summarising its emerging biological roles in inflammation, cancer prevention/treatment and cellular senescence.

Bottom line: this is a chemistry-and-manufacturing-oriented review rather than a pharmacology or clinical paper — useful background on where commercial fisetin actually comes from and how its purity/production route might vary between suppliers, which is relevant context for any product-review discussion of fisetin supplement quality and sourcing.

Key findings

The review surveys fisetin's chemistry as a rare flavonol lacking a 5-hydroxy substituent, summarises multiple synthetic routes for producing pharmaceutical-grade fisetin, and reviews its established antioxidant/cytoprotective and emerging anti-inflammatory, chemopreventive, chemotherapeutic and senotherapeutic biological activities.

What this study can and cannot tell us

This is a narrative review with a chemistry/synthesis focus rather than a systematic review of pharmacological or clinical evidence; its biological-activity summary should be cross-checked against the primary studies it cites rather than taken as a standalone evidence source.

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology